The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double‐blind, methotrexate‐controlled study of patients with active rheumatoid arthritis
Abstract
Objective: To determine the efficacy and safety of pamapimod (a selective inhibitor of the α‐isoform of p38 MAP kinase) as monotherapy in comparison with methotrexate (MTX) treatment in adult patients with active rheumatoid arthritis (RA). Methods: Patients were randomly assigned to 1 of 4 treatment groups and received 12 weeks of double‐blind treatment. One group received MTX (7.5 mg/week with planned escalation to 20 mg/week), and 3 groups received pamapimod (50, 150, or 300 mg) once daily. The primary efficacy end point was the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (achieving an ACR20 response) at 12 weeks. Secondary end points included ACR50 and ACR70 responses, change from baseline in the Disease Activity Score in 28 joints (DAS28), categorical analyses of DAS28/European League Against Rheumatism response, and change from baseline in each parameter of the ACR core set of measures. Safety monitoring included recording of adverse events (AEs), laboratory testing, immunology assessments, administration of electrocardiograms, and assessment of vital signs. Results: Patients assigned to receive MTX and pamapimod had similar demographics and baseline characteristics. At week 12, fewer patients taking pamapimod had an ACR20 response (23%, 18%, and 31% in the 50‐, 150‐, and 300‐mg groups, respectively) compared with patients taking MTX (45%). Secondary efficacy end points showed a similar pattern. AEs were typically characterized as mild and included infections, skin disorders, and dizziness. Pamapimod was generally well tolerated, but the 300‐mg dose appeared to be more toxic than either the 2 lower doses or MTX. Conclusion: The present results showed that pamapimod was not as effective as MTX in the treatment of active RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Cited by
Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis
Bartok, B., & Firestein, G. S. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00859.x · Cited by 1,906
Mitogen-activated protein kinases in innate immunity
Arthur, J. S. C., & Ley, S. C. (2013) · Nature Reviews Immunology · doi:10.1038/nri3495 · Cited by 1,855
Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors
Bottini, N., & Firestein, G. S. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.190 · Cited by 907
Rose, B. A., Force, T., & Wang, Y. (2010) · Physiological Reviews · doi:10.1152/physrev.00054.2009 · Cited by 723
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
Smolen, J. S., & Aletaha, D. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.8 · Cited by 474
The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer
Yong, H.-Y., Koh, M.-S., & Moon, A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903321490 · Cited by 422
Lee, J. K., & Kim, N.-J. (2017) · Molecules · doi:10.3390/molecules22081287 · Cited by 320
Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders.
Fasching, P., Stradner, M., Graninger, W., Dejaco, C., & Fessler, J. (2017) · Molecules · doi:10.3390/molecules22010134 · Cited by 254
Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms
Kleinstreuer, N. C., Yang, J., Berg, E. L., Knudsen, T. B., Richard, A. M., Martin, M. T., Reif, D. M., Judson, R. S., Polokoff, M., Dix, D. J., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2914 · Cited by 211
Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases
Patterson, H., Nibbs, R., McInnes, I., & Siebert, S. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12248 · Cited by 199
Henson, S. M., Macaulay, R., Riddell, N. E., Nunn, C. J., & Akbar, A. N. (2015) · European Journal of Immunology · doi:10.1002/eji.201445312 · Cited by 146
Yin, P., Wang, X., Wang, S., Wei, Y., Feng, J., & Zhu, M. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00466 · Cited by 73
Mitogen-Activated Protein Kinases as Therapeutic Targets for Rheumatoid Arthritis
Paunovic, V., & Harnett, M. M. (2013) · Drugs · doi:10.1007/s40265-013-0014-6 · Cited by 61
The as-yet unfulfilled promise of p38 MAPK inhibitors
Sweeney, S. E. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.171 · Cited by 38
Liposomal glutathione as a promising candidate for immunological rheumatoid arthritis therapy
Kadry, M. O. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02162 · Cited by 29
Yin, P., Wang, S., Wei, Y., Wang, X., Zhang, J., Yin, X., Feng, J., & Zhu, M. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190682 · Cited by 24
Lambert, W. S., Pasini, S., Collyer, J. W., Formichella, C. R., Ghose, P., Carlson, B. J., & Calkins, D. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-65374-6 · Cited by 21
Metadata
- Authors
- Cohen, S. B., Cheng, T., Chindalore, V., Damjanov, N., Burgos‐Vargas, R., DeLora, P., Zimany, K., Travers, H., & Caulfield, J. P.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2009-01-29
- Volume
- 60
- Issue
- 2
- Pages
- 335-344
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2132049460
- Cited by
- 231
- References
- 1
- FWCI
- 18.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.